We were unable to identify a functional or therapeutic capacity of the endogenous tumor-specific antibody response generated by treatment of B78 tumor bearing mice with RT + IT-IC + anti-CTLA-4 (Figures 2, 4). This evidence concerns the gene CTLA4 and neoplasm.